{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T21:20:49Z","timestamp":1768771249561,"version":"3.49.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.ejmech.2020.112492","type":"journal-article","created":{"date-parts":[[2020,7,18]],"date-time":"2020-07-18T10:50:26Z","timestamp":1595069426000},"page":"112492","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In\u00a0vitro and in\u00a0vivo preclinical studies"],"prefix":"10.1016","volume":"204","author":[{"given":"Isabelle Karine da Costa","family":"Nunes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Everton Ten\u00f3rio","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Italo Rossi Roseno","family":"Martins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gisele","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manoel Oliveira de","family":"Moraes Junior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Millena de Melo","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheyla Welma Duarte","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiane Luciano","family":"Balliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bagn\u00f3lia Ara\u00fajo","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patr\u00edcia Machado Rodrigues","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinicius de Frias","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco Aur\u00e9lio","family":"Martins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lidia Moreira","family":"Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2020.112492_bib1","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1741-7015-11-96","article-title":"Phosphodiesterase 4-targeted treatments for autoimmune diseases","volume":"11","author":"Kumar","year":"2013","journal-title":"BMC Med."},{"issue":"3","key":"10.1016\/j.ejmech.2020.112492_bib2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1586\/1744666X.2016.1134319","article-title":"A\u00a0new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast","volume":"12","author":"Chiricozzi","year":"2016","journal-title":"Expet Rev. Clin. Immunol."},{"key":"10.1016\/j.ejmech.2020.112492_bib3","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3389\/fphar.2018.01048","article-title":"Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases","volume":"9","author":"Li","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.ejmech.2020.112492_bib4","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/resp.13276","article-title":"Efficacy and safety of phosphodiesterase 4 inhibitors in patients with asthma: a systematic review and meta-analysis","volume":"23","author":"Luo","year":"2018","journal-title":"Respirology"},{"issue":"2","key":"10.1016\/j.ejmech.2020.112492_bib5","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jaci.2005.04.023","article-title":"Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions","volume":"116","author":"Schalkwyk","year":"2005","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.ejmech.2020.112492_bib6","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.bmcl.2013.12.076","article-title":"Identification of the 5,5-dioxo-7,8-dihydro-6H-thiopyrano[3,2-d]pyrimidine derivatives as highly selective PDE4B inhibitors","volume":"24","author":"Goto","year":"2014","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112492_bib7","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000342380","article-title":"Therapeutic potential of ASP3258, a selective phosphodiesterase 4 inhibitor, on chronic eosinophilic airway inflammation","volume":"90","author":"Kobayashi","year":"2012","journal-title":"Pharmacology"},{"issue":"7","key":"10.1016\/j.ejmech.2020.112492_bib8","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1517\/13543784.10.7.1361","article-title":"Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease","volume":"10","author":"Giembycz","year":"2001","journal-title":"Expet Opin. Invest. Drugs"},{"issue":"8","key":"10.1016\/j.ejmech.2020.112492_bib9","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1080\/00498250400005682","article-title":"Disposition of CP-671, 305, a selective phosphodiesterase 4 inhibitor in preclinical species","volume":"34","author":"Kalgutkar","year":"2004","journal-title":"Xenobiotica"},{"issue":"10","key":"10.1016\/j.ejmech.2020.112492_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162895","article-title":"Synthesis, pharmacological profile and docking studies of new sulfonamides designed as phosphodiesterase-4 inhibitors","volume":"11","author":"Nunes","year":"2016","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.ejmech.2020.112492_bib11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/0929867053363540","article-title":"Bioisosterism: a useful strategy for molecular modification and drug design","volume":"12","author":"Lima","year":"2005","journal-title":"Curr. Med. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2020.112492_bib12","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1021\/cr200060g","article-title":"The methylation effect in medicinal chemistry","volume":"111","author":"Barreiro","year":"2011","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2020.112492_bib13","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1211\/146080899128734370","article-title":"Synthesis and antinociceptive profile of novel acidic sulphonylhydrazone derivatives from natural safrole","volume":"5","author":"Lima","year":"1999","journal-title":"Pharm. Pharmacol. Commun."},{"key":"10.1016\/j.ejmech.2020.112492_bib14","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.2147\/DDDT.S108327","article-title":"Synthesis, solubility, plasma stability, and pharmacological evaluation of novel sulfonylhydrazones designed as anti-diabetic agents","volume":"10","author":"Zapata-Sudo","year":"2016","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejmech.2020.112492_bib15","doi-asserted-by":"crossref","first-page":"7479","DOI":"10.1039\/c2ob26270c","article-title":"Palladium-catalyzed desulfitative arylation of azoles with arylsulfonyl hydrazides","volume":"10","author":"Xinzhang","year":"2012","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2020.112492_bib16","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1055\/s-1973-22208","article-title":"A\u00a0facile alkylation of ethyl 2-oxocyclopentanecarboxylate","volume":"5","author":"Barco","year":"1973","journal-title":"Synthesis-Stuttgart"},{"issue":"7","key":"10.1016\/j.ejmech.2020.112492_bib17","first-page":"392","article-title":"Novel partial agonist of PPAR-gamma for treatment of diabetic neuropathy in rats","volume":"5","author":"Lima","year":"2014","journal-title":"J.\u00a0Diabetes Metabol."},{"issue":"13","key":"10.1016\/j.ejmech.2020.112492_bib18","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1016\/S0040-4020(01)87332-4","article-title":"Conformational behaviour and E\/Z isomerization of N-acyl and N-aroylhydrazones","volume":"42","author":"Palla","year":"1986","journal-title":"Tetrahedron"},{"issue":"17","key":"10.1016\/j.ejmech.2020.112492_bib19","doi-asserted-by":"crossref","first-page":"7525","DOI":"10.1021\/jm300514y","article-title":"Design, synthesis, and pharmacological evaluation of N-acylhydrazones and novel conformationally constrained compounds as selective and potent orally active phosphodiesterase-4 inhibitors","volume":"55","author":"K\u00fcmmerle","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"issue":"13","key":"10.1016\/j.ejmech.2020.112492_bib20","first-page":"3649","article-title":"Studies towards the identification of putative bioactive conformation of potent vasodilator arylidene N-acylhydrazone derivatives","volume":"44","author":"K\u00fcmmerle","year":"2009","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2020.112492_bib21","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.phytol.2008.12.004","article-title":"Rapid solubility determination of the triterpenes oleanolic acid and ursolic acid by UV-spectroscopy in different solvents","volume":"2","author":"Schneider","year":"2009","journal-title":"Phytochem. Lett."},{"issue":"1\u20133","key":"10.1016\/j.ejmech.2020.112492_bib22","first-page":"23","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"23","author":"Lipinski","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"12","key":"10.1016\/j.ejmech.2020.112492_bib23","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112492_bib24","series-title":"Advanced Organic Chemistry: Part A: Structure and Mechanisms","author":"Carey","year":"2008"},{"issue":"3","key":"10.1016\/j.ejmech.2020.112492_bib25","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000368800","article-title":"Phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease","volume":"165","author":"Page","year":"2014","journal-title":"Int. Arch. Allergy Immunol."},{"issue":"3","key":"10.1016\/j.ejmech.2020.112492_bib26","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.pharmthera.2005.07.003","article-title":"Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents","volume":"109","author":"Lugnier","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2020.112492_bib27","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/sj.bjp.0704457","article-title":"Assessing the emetic potential of PDE4 inhibitors in rats","volume":"135","author":"Robichaud","year":"2002","journal-title":"Br. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.ejmech.2020.112492_bib28","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1172\/JCI0215506","article-title":"Deletion of phosphodiesterase 4D in mice shortens \u03b12-adrenoceptor\u2013mediated anesthesia, a behavioral correlate of emesis","volume":"110","author":"Robichaud","year":"2002","journal-title":"J.\u00a0Clin. Invest."},{"issue":"11","key":"10.1016\/j.ejmech.2020.112492_bib29","doi-asserted-by":"crossref","first-page":"7628","DOI":"10.1073\/pnas.122041599","article-title":"Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses","volume":"99","author":"Jin","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"12","key":"10.1016\/j.ejmech.2020.112492_bib30","doi-asserted-by":"crossref","first-page":"14561","DOI":"10.3390\/molecules171214651","article-title":"Synthesis and pharmacological evaluation of novel phenyl sulfonamide derivatives designed as modulators of pulmonary inflammatory response","volume":"17","author":"Barbosa","year":"2012","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2020.112492_bib31","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1183\/09031936.06.00004206","article-title":"Characterisation of Guinea pig precision-cut lung slices: comparison with human tissues","volume":"28","author":"Ressmeyer","year":"2006","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejmech.2020.112492_bib32","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.pupt.2012.08.006","article-title":"Models to study airway smooth muscle contraction in\u00a0vivo, ex\u00a0vivo and in\u00a0vitro: implications in understanding asthma","volume":"26","author":"Wright","year":"2013","journal-title":"Pulm. Pharmacol. Therapeut."},{"issue":"3","key":"10.1016\/j.ejmech.2020.112492_bib33","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1530\/JOE-14-0648","article-title":"Glucagon induces airway smooth muscle relaxation by nitric oxide and prostaglandin E\u2082","volume":"225","author":"Insuela","year":"2015","journal-title":"J.\u00a0Endocrinol."},{"issue":"4","key":"10.1016\/j.ejmech.2020.112492_bib34","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1046\/j.1440-1843.2003.00493.x","article-title":"The airway epithelium: structural and functional properties in health and disease","volume":"8","author":"Knight","year":"2003","journal-title":"Respirology"},{"key":"10.1016\/j.ejmech.2020.112492_bib35","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S0022-3565(25)39237-2","article-title":"Arachidonic acid metabolites and airway epithelium-dependent relaxant factor","volume":"243","author":"Tschirhart","year":"1987","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"issue":"11\u201312","key":"10.1016\/j.ejmech.2020.112492_bib36","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1002\/dta.2523","article-title":"Zebrafish (Danio rerio) water tank model for the investigation of drug metabolism: progress, outlook, and challenges","volume":"10","author":"Sardela","year":"2018","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.ejmech.2020.112492_bib37","series-title":"Collect","author":"Enraf-Nonius","year":"1997"},{"key":"10.1016\/j.ejmech.2020.112492_bib38","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0076-6879(97)76066-X","article-title":"Processing of X-ray diffraction data collected in oscillation mode","volume":"276","author":"Otvinowski","year":"1997","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.ejmech.2020.112492_bib39","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1107\/S0108767394005726","article-title":"An empirical correction for absorption anisotropy","volume":"51","author":"Blessing","year":"1995","journal-title":"Acta Crystallogr."},{"key":"10.1016\/j.ejmech.2020.112492_bib40","series-title":"SHELXS-97","author":"Sheldrick","year":"1997"},{"issue":"4","key":"10.1016\/j.ejmech.2020.112492_bib41","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1107\/S0021889899006020","article-title":"WinGX suite for small-molecule single-crystal crystallography","volume":"32","author":"Farrugia","year":"1999","journal-title":"J.\u00a0Appl. Crystallogr."},{"key":"10.1016\/j.ejmech.2020.112492_bib42","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1107\/S0021889897003117","article-title":"ORTEP-3 for windows - a version of ORTEP-III with a graphical user interface (GUI)","volume":"30","author":"Farrugia","year":"1997","journal-title":"J.\u00a0Appl. Crystallogr."},{"key":"10.1016\/j.ejmech.2020.112492_bib43","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jsbmb.2013.05.009","article-title":"Nongenomic bronchodilating action elicited by dehydroepiandrosterone (DHEA) in a Guinea pig asthma model","volume":"138","author":"Espinoza","year":"2013","journal-title":"J.\u00a0Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.ejmech.2020.112492_bib44","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1021\/jm970530e","article-title":"Physicochemical high throughput screening: Parallel artificial membrane permeation assay in the description of passive absorption processes","volume":"41","author":"Kansy","year":"1998","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112492_bib45","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1021\/jm990968+","article-title":"Predicting blood-brain barrier permeation from three-dimensional molecular structure","volume":"43","author":"Crivori","year":"2000","journal-title":"J.\u00a0Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2020.112492_bib46","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0223-5234(03)00012-6","article-title":"High throughput artificial membrane permeability assay for blood\u2013brain barrier","volume":"38","author":"Di","year":"2003","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112492_bib47","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.bmc.2016.12.049","article-title":"Highly predictive and interpretable models for PAMPA permeability","volume":"25","author":"Sun","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112492_bib48","series-title":"Importance and applications of cell- and tissue-based in\u00a0vitro models for drug permeability screening in early stages of drug development. Cell and Tissue Based in\u00a0vitro Culture Models","first-page":"3","author":"Cabrera-p\u00e9rez","year":"2016"},{"key":"10.1016\/j.ejmech.2020.112492_bib49","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.tips.2019.10.006","article-title":"Phosphodiesterase type 4 inhibition in CNS diseases","volume":"40","author":"Blokland","year":"2019","journal-title":"Trends Pharmacol. Sci."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420304645?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420304645?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:12:41Z","timestamp":1759327961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523420304645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":49,"alternative-id":["S0223523420304645"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112492","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In\u00a0vitro and in\u00a0vivo preclinical studies","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112492","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112492"}}